SGLT2 inhibitors reduces heart failure and increases lifespan of people with cancer and diabetes

The use of SGLT2 inhibitors was associated with a reduced risk of heart failure in people living with cancer and diabetes, according to research published in the British Medical Journal.

The FDA-approved drug has also been found to increase the lifespan of individuals living with the two conditions, the study has reported.

During the trial, a team of researchers looked at the health outcomes of 8,640 people, all of whom had cancer and diabetes.

They found that the participants using SGLT2 inhibitors (SGLT2i) had a threefold lower rate of hospitalisation for incident heart failure compared to those not using the drug.

The use of SGLT2i was also associated with a higher mortality rate, the research study has identified.

The study can now be accessed here.